ArticleACS applied materials & interfaces2025
Synergistic Cancer Metabolic Therapy via Co-Delivery of 3-Bromopyruvate and Temozolomide with a Supramolecular Shuttle.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combination therapy has shown promise in treating aggressive cancers by using several drugs simultaneously to target different biological pathways, with the added benefit of potentially reducing toxicity. Given the critical role of mitochondrial dysfunction in tumor progression, targeting mitochondrial metabolism represents a promising therapeutic avenue. In this study, we developed a mitochondria-targeted nanofiber based on self-assembling peptides, engineered to co-deliver two complementary therapeutic agents for glioblastoma treatment. The nanofiber carries 1,3-bromopyruvate (BrP), a glycolysis inhibitor, and temozolomide, an alkylating chemotherapeutic, conjugated via a matrix metalloproteinase-9 (MMP-9)-responsive linker for controlled, on-demand release. To enhance selectivity for glioblastoma cells, the nanofiber surface was functionalized with the targeting peptide falGea binding specifically to EGFRvIII, commonly overexpressed in tumor cells, and gH625, a cell-penetrating peptide known to facilitate the blood-brain barrier (BBB) transport. The nanofibers were comprehensively characterized for their aggregation behavior, structural stability, and morphology. Mitochondrial targeting and functional effects were evaluated by using isolated rat brain mitochondria. Therapeutic efficacy was assessed in U-87 MG glioblastoma cells cultured in both 2D and 3D systems. Additionally, BBB permeability was examined by using a dynamic 3D in vitro BBB model, demonstrating the transport-enhancing role of gH625. These findings support the potential of multifunctional, mitochondria-targeted nanofibers as an effective platform for glioblastoma therapy, offering both precision targeting and enhanced drug delivery across the BBB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.